Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03692429 · ClinicalTrials.gov registry record · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
A Phase 1 study of Unresectable Metastatic Colorectal Cancer, sponsored by Celyad Oncology.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
- 4
- Study locations
NCT03692429: Recruiting Phase 1 study of Unresectable Metastatic Colorectal Cancer, sponsored by Celyad Oncology.
NCT03692429 is a Phase 1 study of Unresectable Metastatic Colorectal Cancer that is actively recruiting participants, run by Celyad Oncology. The registered enrollment target is 49 participants, below the 135-participant average among 3 other Unresectable Metastatic Colorectal Cancer trials with a reported enrollment target (64% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03692429, a Phase 1 study of Unresectable Metastatic Colorectal Cancer, is actively recruiting participants, sponsored by Celyad Oncology.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of the alloSHRINK study is to assess the safety, cell kinetics and clinical activity of CYAD-101 in patients with unresectable metastatic colorectal cancer administered after standard chemotherapy
Conditions Studied
Interventions
- DRUG FOLFIRI
- DRUG CYAD-101
- DRUG FOLFOX
Study Locations (4)
Other
- Institut Jules Bordet - Brussels
- UZ Antwerpen - Edegem
- UZ Leuven - Leuven
Florida
- Moffit Cancer Center - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2018-11-28 |
| Est. Completion | 2036-02-17 |
| Phase | Phase 1 |
What NCT03692429 shows while recruiting
NCT03692429 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 135-participant average among 3 other Unresectable Metastatic Colorectal Cancer trials with a reported enrollment target (64% lower).
The record links to 1 condition, with Unresectable Metastatic Colorectal Cancer appearing as the primary indexed condition, and to 3 interventions - of which FOLFIRI is the first listed.
NCT03692429 reports a single indexed study location in Other, Florida.
Frequently Asked Questions
What is clinical trial NCT03692429 about?
NCT03692429 is a clinical study titled "alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells". The purpose of the alloSHRINK study is to assess the safety, cell kinetics and clinical activity of CYAD-101 in patients with unresectable metastatic colorectal cancer administered after standard chemotherapy
What is the current status of trial NCT03692429?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2018-11-28. Estimated completion is 2036-02-17.
What conditions does trial NCT03692429 study?
This clinical trial studies the following conditions: Unresectable Metastatic Colorectal Cancer.
What interventions are being tested in trial NCT03692429?
The interventions under investigation include: FOLFIRI (DRUG), CYAD-101 (DRUG), FOLFOX (DRUG).
Who is sponsoring clinical trial NCT03692429?
This trial is sponsored by Celyad Oncology, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03692429 being conducted?
This trial has 4 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Unresectable Metastatic Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer
RECRUITING · Phase 1
-
Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer
RECRUITING · Phase 1
-
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
- NCT04883437 · 49 participants · Phase 2
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI